Role of Interleukin-1β and Prostaglandin E2 in Prediction and Outcome of Apnea in Neonates

Benha University

Status: Completed

Conditions: Premature Newborns With Gestational Age 28 to 33 Weeks; Premature Newborns

Treatments: Diagnostic Test: Blood test

Study type: Observational

Funder types: Other

Identifiers

NCT06827197

MS 4-5-2023

Details and patient eligibility

About

Our thesis proposed that IL-1β may affect brainstem respiratory control via prostaglandin-dependant mechanism so we investigated the mediator roles of IL-1β and PGE2 levels in predicting apnea in pretertm newborn and their relation to clinical outcomes.

Enrollment: 100 patients

Sex: All

Ages: 1 day to 2 months old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Preterm infants born at less than 37 weeks of gestation.
• Neonates aged from birth up to 28 days.
• Neonates diagnosed with apnea of prematurity or exhibiting apneic episodes

Exclusion criteria

• Full-term neonates.
• Neonates with major congenital malformations or genetic syndromes.
• Neonates with severe neurological impairments (e.g., intraventricular hemorrhage grade III or IV).
• Neonates with confirmed or suspected sepsis or active infections.
• Neonates receiving steroids, nonsteroidal anti-inflammatory drugs (NSAIDs), or other medications known to alter interleukin-1β or prostaglandin E2 levels.
• Neonates with congenital heart diseases.
• Neonates with a history of significant birth asphyxia requiring extensive resuscitation.
• Neonates whose parents or guardians refuse to provide informed consent.